A multi-centric, open-labeled, prospective, comparative study to evaluate the efficacy and safety of Tinefcon and standard of care versus standard of care alone in patients of moderate COVID-19 - TINEFCO

Piramal Enterprises Limited0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1. Subjects who are able to provide a written informed consent or have a legally accepted representative to provide the same.
•2.Subjects who are proven to be positive for SARS-CoV-2 infection, as confirmed by the RT-PCR test.
•3.Subjects who are admitted with moderate COVID-19 (MOFHW criteria) for treatment at the hospital having the following clinical criteria: pneumonia with no signs of severe disease; peripheral capillary oxygen saturation (SPO2) between 90 and 94% on room air and respiratory rate between 15 and 30 breaths per minute.
•4.Subjects with arterial partial pressure of oxygen/fraction of inspired oxygen (PaO2/FiO2) between 200 and 300 mm/Hg.
•5.Female subjects with a negative urine pregnancy test at screening.
•6.Subjects who are able to take the study drug orally and comply with the study procedures

•1. Subjects who are participating in any other clinical trial or experimental treatment for COVID-19.
•2.Subjects with persistent vomiting (more than three episodes of vomiting in 12 hours) and who cannot tolerate oral drugs.
•3.Subjects requiring concomitant use of invasive or non-invasive mechanical ventilation.
•4.Subjects requiring vasopressors or ionotropic medications.
•5.Subjects requiring anti-viral drugs like ritonavir, favipirir, lopinavir or monoclonal antibodies like tocilizumab at hospitalization, in the opinion of the Investigator.
•6.Female subjects who are pregnant or lactating.
•7.Subjects who are known to be HIV positive or positive for Hepatitis B or C. (The same may be noted based on history given by the subject or standards of care followed at the individual sites.)
•8.Subjects with history of retinopathy or macular degeneration.
•9.Subjects with prolonged QTc interval at screening ( >450 ms in males and >470 ms in females).
•10.Subjects with liver enzymes (namely alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST)) > 5x upper limit of normal.
•11.Subjects with creatinine clearance <50 ml/min (using Cockgroft-Gault formula).
•12.Subjects who are not deemed fit as per the investigator for any other medical reason

发起方